AGTX (Agentix) EBITDA Margin %: 0.00% (As of Dec. 2025)


What is Agentix EBITDA Margin %?

Agentix AGTX -8.09% EBITDA Margin % is 0.00% as of Dec. 2025. The stock has 3 warning signs investors should review. Among 945 Biotechnology companies, Agentix ranks worse than 105820% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Agentix's EBITDA for the three months ended in Dec. 2025 was $-0.07 Mil. Agentix's Revenue for the three months ended in Dec. 2025 was $0.00 Mil. Therefore, Agentix's EBITDA margin for the quarter that ended in Dec. 2025 was 0.00%.

Agentix  (OTCPK:AGTX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Agentix EBITDA Margin % Related Terms

Agentix EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Agentix's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Agentix EBITDA Margin % Chart

Agentix Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Mar23 Mar24 Mar25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -134,000.00 0.00 0.00 0.00

Agentix Quarterly Data
Feb21 May21 Aug21 Nov21 Feb22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

AGTX vs CERO, EVFM, EMMA: EBITDA Margin % Comparison

For the Biotechnology subindustry, Agentix's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Agentix EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agentix's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Agentix's EBITDA Margin % falls into.


Agentix EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Agentix's EBITDA Margin % for the fiscal year that ended in Mar. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Mar. 2025 )/Revenue (A: Mar. 2025 )
=-0.524/0
= %

Agentix's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-0.065/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Agentix (AGTX) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Agentix and its competitors. According to the industry distribution chart, Agentix ranks #999999 out of 945 companies in the Biotechnology industry.
Is Agentix's EBITDA Margin % too high?
Agentix's current EBITDA Margin % is 0.00%. Based on the distribution chart, Agentix ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Agentix's EBITDA Margin % compare to CERO and EVFM?
According to the Biotechnology industry distribution chart, Agentix ranks #999999 out of 945 companies for EBITDA Margin %. This places Agentix in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Agentix and its competitors. Agentix's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agentix stock overvalued right now?
Agentix (AGTX) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Agentix (AGTX), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Agentix Business Description

Address 32932 Pacific Coast Highway, No. 14-254, Dana Point, CA, USA, 92629
Agentix Corp is a biotechnology company. Through its subsidiary, it is engaged in the development and commercialization of novel therapeutics to treat metabolic diseases, peripheral neuropathy, progressive lung disease, and ischemic reperfusion injury. Its principal business objective is to develop both science-driven synthetic and natural cannabinoid therapeutics that address unmet medical needs and continue to drive innovations in the endocannabinoid space. Its pipeline of drug candidates includes AGTX-2004, a CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus (T2DM), and AGTX-2003 a peripherally-acting CB1 receptor inverse agonist that has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver disease.